Amal Abu Sabaa

Clinical and Molecular Studies of Diffuse Large B-cell Lymphoma

Abu Sabaa, Amal

2023

• Ladda ner fulltext (pdf) av Clinical and Molecular Studies of Diffuse Large B-cell Lymphoma

Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls

Sabaa, Amal Abu; Shen, Qiujin; Lennmyr, Emma; Enblad, Anna Pia et al.

Ingår i New Biotechnology, s. 21-29, 2022

• DOI för Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls
• Ladda ner fulltext (pdf) av Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Sabaa, Amal Abu; Mörth, Charlott; Hasselblom, Sverker; Hedström, Gustaf et al.

Ingår i British Journal of Haematology, s. 906-914, 2021

• DOI för Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study
• Ladda ner fulltext (pdf) av Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Mörth, Charlott; Sabaa, Amal Abu; Freyhult, Eva; Christersson, Christina et al.

Ingår i Cardio-Oncology, 2021

• DOI för Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma
• Ladda ner fulltext (pdf) av Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome

Mörth, Charlott; Valachis, Antonios; Sabaa, Amal Abu; Marshall, Katharina et al.

Ingår i Acta Oncologica, s. 1170-1177, 2019

• DOI för Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome

Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls

Sabaa, Amal Abu; Shen, Qiujin; Lennmyr, Emma; Enblad, Anna Pia et al.

Ingår i New Biotechnology, s. 21-29, 2022

• DOI för Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls
• Ladda ner fulltext (pdf) av Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Sabaa, Amal Abu; Mörth, Charlott; Hasselblom, Sverker; Hedström, Gustaf et al.

Ingår i British Journal of Haematology, s. 906-914, 2021

• DOI för Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study
• Ladda ner fulltext (pdf) av Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Mörth, Charlott; Sabaa, Amal Abu; Freyhult, Eva; Christersson, Christina et al.

Ingår i Cardio-Oncology, 2021

• DOI för Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma
• Ladda ner fulltext (pdf) av Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome

Mörth, Charlott; Valachis, Antonios; Sabaa, Amal Abu; Marshall, Katharina et al.

Ingår i Acta Oncologica, s. 1170-1177, 2019

• DOI för Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome

Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Mörth, Charlott; Valachis, Antonis; Sabaa, Amal Abu; Molin, Daniel et al.

Ingår i Annals of Hematology, s. 2129-2135, 2018

• DOI för Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
• Ladda ner fulltext (pdf) av Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Does the omission of vincristine affect outcome and survival in patients with diffuse large B-cell lymphoma?

Mörth, Charlott; Valachis, Antonis; Abu Sabaa, Amal; Hedström, Gustaf et al.

Ingår i Annals of Oncology, 2017

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving EFS24 - a Swedish population-based study.

Sabaa, Amal Abu; Mörth, Charlott; Hasselblom, Sverker; Hedström, Gustaf et al.

Clinical and Molecular Studies of Diffuse Large B-cell Lymphoma

Abu Sabaa, Amal

2023

• Ladda ner fulltext (pdf) av Clinical and Molecular Studies of Diffuse Large B-cell Lymphoma

T-cell Leukaemia/Lymphoma Protein 1A (TCL1A) In Diffuse Large B-cell lymphoma (DLBCL)

Abu Sabaa, Amal; Mörth, Charlott; Berglund, Mattias; Hashemi, Jamileh et al.

Plasma Protein Profiling using Multiplex Extension Assay in Diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: A descriptive study

Abu Sabaa, Amal; Mörth, Charlott; Molin, Daniel; Freyhult, Eva et al.